Astellas reports Xtandi sales, Medivation rallies

|About: Astellas Pharma, Inc. ADR (ALPMY)|By:, SA News Editor

Astellas Pharma (ALPMY) reports H1 consolidated net sales ( ¥ millions) of ¥556,702, up 16.7% Y/Y.

Net income ( ¥ millions) for H1 falls 16% Y/Y to ¥48.195. (full results)

Xtandi U.S. sales of ~$190M for April-September. (supplementary documents)

Backing out FQ1 sales of $82M gets ~$108M in U.S. Xtandi sales for FQ2.

These numbers are likely behind the rally in shares of Medivation (MDVN +10.1%), Astellas' Xtandi partner.